Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Diazoxide

FDA-approved product (injectable, injection), marketed as Diazoxide, Hyperstat, Proglycem and 1 more.

Registered studies
39
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Diazoxide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hyperinsulinism
  • Hypertension
  • Hypoglycemia
  • Pancreatic insulinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazide derivatives; Drugs for treatment of hypoglycemia
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Diazoxide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Diazoxide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Diazoxide in the Treatment of Type 1 Glycogenosis

    NCT07739394 · start 2026-08-30

    Registered record
    Registry ID
    NCT07739394
    Conditions
    Glycogen Storage Disease Type I
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-08-30
    Completion
    2027-10-15
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlycogen Storage Disease Type I
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Effect of Insulin Lowering on Lipogenesis

    NCT07403604 · start 2026-07-01

    Registered record
    Registry ID
    NCT07403604
    Conditions
    Hyperinsulinemia; Insulin Resistance; Non-Alcoholic Fatty Liver Disease; Prediabetic State; Obesity
    Interventions
    Placebo; Diazoxide Oral Suspension, 2 mg per kg per dose; Deuterated water (2H2O/D2O), 70%; Insulin Suppression Test (IST)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-07-01
    Completion
    2029-09-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperinsulinemia; Insulin Resistance; Non-Alcoholic Fatty Liver Disease; Prediabetic State +1 more
    InterventionPlacebo; Diazoxide Oral Suspension, 2 mg per kg per dose; Deuterated water (2H2O/D2O), 70%; Insulin Suppression Test (IST)
    PhasePhase 1
    Registry statusRecruiting

  • Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

    NCT07450664 · start 2025-11-26

    Registered record
    Registry ID
    NCT07450664
    Conditions
    Prader-Willi Syndrome
    Interventions
    VYKAT XR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2025-11-26
    Completion
    2028-03-02
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionVYKAT XR
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Diazoxide Suppression Test P&F Study

    NCT06606327 · start 2024-10-23

    Registered record
    Registry ID
    NCT06606327
    Conditions
    Insulin Resistance; Hyperinsulinemia; Obesity
    Interventions
    Diazoxide, 3 mg/kg per dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2024-10-23
    Completion
    2026-06-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsulin Resistance; Hyperinsulinemia; Obesity
    InterventionDiazoxide, 3 mg/kg per dose
    PhasePhase 1
    Registry statusTerminated

  • Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial

    NCT06308107 · start 2024-07-08

    Registered record
    Registry ID
    NCT06308107
    Conditions
    Myocardial Stunning
    Interventions
    IV Diazoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-07-08
    Completion
    2025-05-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Stunning
    InterventionIV Diazoxide
    PhasePhase 1
    Registry statusCompleted

  • Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward

    NCT06277947 · start 2024-02

    Registered record
    Registry ID
    NCT06277947
    Conditions
    Epithelial Ovarian Cancer
    Interventions
    China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-02
    Completion
    2025-05
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpithelial Ovarian Cancer
    InterventionChina Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)
    PhaseNot applicable
    Registry statusUnknown

  • Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

    NCT04830982 · start 2023-09-01

    Registered record
    Registry ID
    NCT04830982
    Conditions
    Myocardial Stunning
    Interventions
    IV Diazoxide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2023-09-01
    Completion
    2025-10-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Stunning
    InterventionIV Diazoxide; Placebo
    PhasePhase 1
    Registry statusWithdrawn

  • Glycemic Effect of Diazoxide in NAFLD

    NCT05729282 · start 2023-08-01

    Registered record
    Registry ID
    NCT05729282
    Conditions
    Hyperinsulinemia; Insulin Resistance; Non-Alcoholic Fatty Liver Disease; Prediabetic State
    Interventions
    Diazoxide oral suspension, 1 mg per kg per dose; Diazoxide oral suspension, 2 mg per kg per dose; Placebo; FreeStyle Libre Pro; Deuterated water (2H2O/D2O)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-08-01
    Completion
    2025-09-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperinsulinemia; Insulin Resistance; Non-Alcoholic Fatty Liver Disease; Prediabetic State
    InterventionDiazoxide oral suspension, 1 mg per kg per dose; Diazoxide oral suspension, 2 mg per kg per dose; Placebo; FreeStyle Libre Pro +1 more
    PhasePhase 1
    Registry statusCompleted

  • Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

    NCT05701774 · start 2023-01-31

    Registered record
    Registry ID
    NCT05701774
    Conditions
    Prader-Willi Syndrome
    Interventions
    DCCR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-01-31
    Completion
    2028-06
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionDCCR
    PhasePhase 3
    Registry statusActive not recruiting

  • An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

    NCT05532020 · start 2023-01

    Registered record
    Registry ID
    NCT05532020
    Conditions
    SH2B1 Deficiency Obesity; Obesity Associated With PCSK1 Mutation (rs6232 Variant); SIM1 Deficiency Obesity
    Interventions
    DCCR (diazoxide choline) extended-release tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-01
    Completion
    2024-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSH2B1 Deficiency Obesity; Obesity Associated With PCSK1 Mutation (rs6232 Variant); SIM1 Deficiency Obesity
    InterventionDCCR (diazoxide choline) extended-release tablets
    PhasePhase 2
    Registry statusUnknown

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • An Open-Label Study of DCCR Tablet in Patients With PWS

    NCT04086810 · start 2019-10

    Registered record
    Registry ID
    NCT04086810
    Conditions
    Prader-Willi Syndrome
    Interventions
    DCCR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-10
    Completion
    2019-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionDCCR
    PhasePhase 3
    Registry statusWithdrawn

  • The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

    NCT03685773 · start 2019-04-21

    Registered record
    Registry ID
    NCT03685773
    Conditions
    Diabetes Mellitus, Type 2; Glucose, High Blood; Glucose Metabolism Disorders
    Interventions
    Diazoxide; Placebo (for diazoxide); Nicotinic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-04-21
    Completion
    2023-04-21
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Glucose, High Blood; Glucose Metabolism Disorders
    InterventionDiazoxide; Placebo (for diazoxide); Nicotinic acid
    PhasePhase 2
    Registry statusWithdrawn

  • Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

    NCT03608163 · start 2019-01-08

    Registered record
    Registry ID
    NCT03608163
    Conditions
    Diabetes Mellitus, Type 1; Hypoglycemia; Hypoglycemia Unawareness
    Interventions
    Naloxone; Diazoxide; Placebo (for Naloxone); Placebo (for Diazoxide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-01-08
    Completion
    2019-08-22
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1; Hypoglycemia; Hypoglycemia Unawareness
    InterventionNaloxone; Diazoxide; Placebo (for Naloxone); Placebo (for Diazoxide)
    PhasePhase 4
    Registry statusTerminated

  • Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

    NCT03714373 · start 2018-10-01

    Registered record
    Registry ID
    NCT03714373
    Conditions
    Prader-Willi Syndrome
    Interventions
    DCCR; DCCR; Placebo for DCCR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-01
    Completion
    2023-08-17
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionDCCR; DCCR; Placebo for DCCR
    PhasePhase 3
    Registry statusCompleted